A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer — Stella
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Trial locations(9 sites)
China
Wenzhou Medical University Affiliated Second Hospital, Wenzhou, Zhejiang
Peking University First Hospital, Beijing
Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu
Zhujiang Hospital, Southern Medical University, Guangzhou
Jiangxi Cancer Hospital, Nanchang
Jiangsu Province Hospital, Nanjing
Fudan University Shanghai Cancer Center, Shanghai
Hubei Cancer Hospital, Wuhan
Subei People's Hospital of Jiangsu province, Yangzhou